Home โ€บ Stories โ€บ Stocks
๐ŸŸก Watch

AstraZeneca in $400bn talks to buy Bristol Myers Squibb

Seven outlets independently confirm megadeal talks, but no BMS price data has landed yet.

Buzz velocity12.2ร—

What's happening

The Guardian, CNBC, Reuters (twice), and FT-sourced reports all say AstraZeneca held talks with Bristol Myers Squibb on a roughly $400 billion merger. The story broke and re-broke across a full day, with Reuters and CNBC both citing the FT as the original source and adding their own confirmations.

The numbers

Velocity 12.2 is the highest in this batch, breadth 3, and 37 recent mentions โ€” the loudest story on the board today. No BMS price/verdict was captured, though AstraZeneca shares reportedly fell 7% on the report.

Our read

Seven independent outlets converging on a specific dollar figure is not noise โ€” this is a corroborated deal story, not speculation from one source. Verdict: watch, pending confirmed BMS price action; the AZN drop suggests the market's first read favors the seller, not the acquirer. Watch for an official confirmation or denial from either company.

Sources we checked

See today's live board

This story is frozen as published on August 3, 2026. The live board shows what is moving right now, scored against real money.

Open this story live โ†’ See today's live board

More Stocks stories

Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything โ€” you decide.

Get Sort Brick Daily - free, every evening

One short email every evening: what really moved, what was only noise, and what we logged first, with the times. Free. Information, not investment advice.

No spam. One click to unsubscribe. Sent by Sort Brick.